These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 33165509)

  • 21. Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
    Verstockt B; Volk V; Jaeckel C; Alsoud D; Sabino J; Nikolaus S; Outtier A; Krönke N; Feuerhake F; De Hertogh G; Rosenstiel P; Vermeire S; Schreiber S; Ferrante M; Aden K
    Aliment Pharmacol Ther; 2022 Jul; 56(2):282-291. PubMed ID: 35484689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Investigating the association between the tissue expression of miRNA-101, JAK2/STAT3 with TNF-α, IL-6, IL-1β, and IL-10 cytokines in the ulcerative colitis patients.
    Voshagh Q; Anoshiravani A; Karimpour A; Goodarzi G; Tehrani SS; Tabatabaei-Malazy O; Panahi G
    Immun Inflamm Dis; 2024 Mar; 12(3):e1224. PubMed ID: 38517042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling.
    Nieminen JK; Niemi M; Sipponen T; Salo HM; Klemetti P; Färkkilä M; Vakkila J; Vaarala O
    PLoS One; 2013; 8(8):e70738. PubMed ID: 23950992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
    Morelli M; Scarponi C; Mercurio L; Facchiano F; Pallotta S; Madonna S; Girolomoni G; Albanesi C
    J Immunol Res; 2018; 2018():7897263. PubMed ID: 30581877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of JAK-STAT pathway corrects salivary gland inflammation and interferon driven immune activation in Sjögren's disease.
    Gupta S; Yamada E; Nakamura H; Perez P; Pranzatelli TJ; Dominick K; Jang SI; Abed M; Martin D; Burbelo P; Zheng C; French B; Alevizos I; Khavandgar Z; Beach M; Pelayo E; Walitt B; Hasni S; Kaplan MJ; Tandon M; Magone MT; Kleiner DE; Chiorini JA; Baer A; Warner BM
    Ann Rheum Dis; 2024 Jul; 83(8):1034-1047. PubMed ID: 38527764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating Immunologic Signaling Networks: The JAK/STAT Pathway in Colitis and Colitis-Associated Cancer.
    Zundler S; Neurath MF
    Vaccines (Basel); 2016 Feb; 4(1):. PubMed ID: 26938566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The JAK-Inhibitor Tofacitinib Rescues Human Intestinal Epithelial Cells and Colonoids from Cytokine-Induced Barrier Dysfunction.
    Sayoc-Becerra A; Krishnan M; Fan S; Jimenez J; Hernandez R; Gibson K; Preciado R; Butt G; McCole DF
    Inflamm Bowel Dis; 2020 Feb; 26(3):407-422. PubMed ID: 31751457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tofacitinib counteracts IL-6 overexpression induced by deficient autophagy: implications in Sjögren's syndrome.
    Barrera MJ; Aguilera S; Castro I; Matus S; Carvajal P; Molina C; González S; Jara D; Hermoso M; González MJ
    Rheumatology (Oxford); 2021 Apr; 60(4):1951-1962. PubMed ID: 33216905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.
    Palasik BN; Wang H
    J Pharm Pract; 2021 Dec; 34(6):913-921. PubMed ID: 32873116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of microRNA-495 improves the intestinal mucosal barrier function by targeting STAT3 via inhibition of the JAK/STAT3 signaling pathway in a mouse model of ulcerative colitis.
    Chu XQ; Wang J; Chen GX; Zhang GQ; Zhang DY; Cai YY
    Pathol Res Pract; 2018 Jan; 214(1):151-162. PubMed ID: 29129493
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation.
    Suzuki A; Hanada T; Mitsuyama K; Yoshida T; Kamizono S; Hoshino T; Kubo M; Yamashita A; Okabe M; Takeda K; Akira S; Matsumoto S; Toyonaga A; Sata M; Yoshimura A
    J Exp Med; 2001 Feb; 193(4):471-81. PubMed ID: 11181699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
    De Vries LCS; Wildenberg ME; De Jonge WJ; D'Haens GR
    J Crohns Colitis; 2017 Jul; 11(7):885-893. PubMed ID: 28158411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The JAK inhibitor tofacitinib ameliorates immune‑mediated liver injury in mice.
    Wang H; Feng X; Han P; Lei Y; Xia Y; Tian D; Yan W
    Mol Med Rep; 2019 Dec; 20(6):4883-4892. PubMed ID: 31638166
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of JAK inhibitors in Crohn's Disease.
    Rogler G
    J Crohns Colitis; 2020 Aug; 14(Supplement_2):S746-S754. PubMed ID: 31781755
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tofacitinib in ulcerative colitis.
    Archer TP; Moran GW; Ghosh S
    Immunotherapy; 2016 May; 8(5):495-502. PubMed ID: 27140405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of signal transducer and activator of transcription (STAT) 1 in human chronic inflammatory bowel disease.
    Schreiber S; Rosenstiel P; Hampe J; Nikolaus S; Groessner B; Schottelius A; Kühbacher T; Hämling J; Fölsch UR; Seegert D
    Gut; 2002 Sep; 51(3):379-85. PubMed ID: 12171960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ex vivo effect of JAK inhibition on JAK-STAT1 pathway hyperactivation in patients with dominant-negative STAT3 mutations.
    Lobo PB; Guisado-Hernández P; Villaoslada I; de Felipe B; Carreras C; Rodriguez H; Carazo-Gallego B; Méndez-Echevarria A; Lucena JM; Aljaro PO; Castro MJ; Noguera-Uclés JF; Milner JD; McCann K; Zimmerman O; Freeman AF; Lionakis MS; Holland SM; Neth O; Olbrich P
    J Clin Immunol; 2022 Aug; 42(6):1193-1204. PubMed ID: 35507130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
    Ibrahim SSA; Salama MA; Selima E; Shehata RR
    Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tofacitinib Affects M1-like and M2-like Polarization and Tissue Factor Expression in Macrophages of Healthy Donors and IBD Patients.
    Lethen I; Lechner-Grimm K; Gabel M; Knauss A; Atreya R; Neurath MF; Weigmann B
    Inflamm Bowel Dis; 2024 Jul; 30(7):1151-1163. PubMed ID: 38142236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5.
    Fuss IJ; Neurath M; Boirivant M; Klein JS; de la Motte C; Strong SA; Fiocchi C; Strober W
    J Immunol; 1996 Aug; 157(3):1261-70. PubMed ID: 8757634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.